Benjamin L Maughan

Great collaboration, showing another angle of just how different RMC is from ccRCC. It is very FDG avid in addition to being chemo and radiation responsive. Truly just a very different disease.@_ShankarSiva @MihirShanker @AlexSherryMD @ndesai2005 @ebludmir @OncHahn

On #WorldKidneyCancerDay, we are thinking about the 85% of kidney cancer patients who experience emotional challenges, according to the 2025 Global Patient Survey on Kidney Cancer. (1/3)

⚡️ On @EUplatinum - ctDNA positivity in high-grade pT1 urothelial bladder cancer predicts significantly shorter OS, independently of clinical risk group, age, or sex. A new prognostic layer beyond current staging — detected with a urine-based somatic mutation test. sciencedirect.com/science/articl… #BladderCancer

PTEN loss is associated with worse outcomes in prostate cancer. Now there's a way to act on it in the hormone-sensitive setting. 🎯 CAPItello-281: capivasertib + abiraterone improved rPFS in PTEN-deficient mHSPC, 33.2 vs 25.7 mo, HR 0.81. FDA approved this month, PTEN by IHC. ⚠️ The AKT inhibitor adds hyperglycemia, diarrhea, and rash, including grade 3 rash. 🏥 Plan for it: check glucose at baseline and on treatment with metformin ready, antihistamine prophylaxis for rash, loperamide early for diarrhea (onset around day 9). Why this matters for your practice: 💡 The supportive care and counseling need to be set up early before the first dose. What are you recommendations for handling glucose and skin monitoring for these patients? 🩺 👉CAPItello-281 full results: bit.ly/capitello281-m… #ProstateCancer #GUOnc

Today is World Kidney Cancer Day and the final day of the KCA Challenge: 81K Strong. There's still time to take on a one-day challenge: 🚶 81-minute walk 🚲 8.1-mile bike ride 💧 81 ounces of water 🧡 Donate $8.10, $81, or $810 👉 Join the challenge at charity.pledgeit.org/2026challenge

Excited to see this paper come out. Amazing collaboration across disease sites and shoutout to @AlexSherryMD for leading. Look soon for first results of the larger EXTEND-OP study, phase II basket study investigating mdt for oligoprogression 320/410 accrued. Led by @ebludmir

KidneyCAN CEO Bryan Lewis recently attended the 2026 ASCO Annual Meeting, where researchers, clinicians, advocates, and industry leaders gathered to share the latest advances in cancer research and care. It was a great opportunity to reconnect with colleagues, learn about emerging science, and continue important conversations about accelerating progress for #KidneyCancer patients. Want to explore some of the latest research presented at ASCO? ASCO's patient-friendly research summaries are a great place to start: asco.org/practice-patie… #ASCO26 #AcceleratingCures

💜 When was your last checkup? This #MensHealthWeek, take a few minutes to invest in your health: ✔️ Schedule your annual physical ✔️ Perform a monthly testicular self-exam ✔️ Talk to your doctor about any concerns Early detection saves lives. Share this post and remind the men in your life that their health matters. #testicularcancer #urology

Out now in @JCO_ASCO and @CircAHA: Our @American_Heart & @ASCO joint scientific statement on defining cardiovascular (CV) endpoints in oncology trials👉a framework for asking CV safety questions before trials begin👉Article link in the last post 👇#CardioOncology #CardioTwitter. @OncoAlert @US_FDA

fantastic Best of ASCO here in Austin with @TotalHealthConf - all-star lineup including @MikeLattanzi from @TexasOncology🎉 great updates ASCO presos from @MattGalsky @DrChoueiri @neerajaiims and more! @SitemanCenter @WashUOncology #ASCO26

⚡️ The FDA has approved adjuvant belzutifan + pembrolizumab for clear cell RCC at intermediate-high risk of recurrence after nephrectomy. LITESPARK-022 data: HR 0.72 (95% CI 0.59–0.87; p=0.0003) in DFS vs pembrolizumab alone. Median DFS not reached in either arm. A meaningful step forward in a setting where we needed better options. cancernetwork.com/view/fda-appro… #KidneyCancer

Not many prostate bispecifics in the oral sessions at ASCO this year. Most of the activity was in the posters. Four programs, four targets: 🔬 STEAP1 × CD3, xaluritamig + abiraterone (Sumey, 5070): the only one with efficacy data. PSA50 65%, RECIST ORR 57% in taxane-naïve mCRPC. Inphase 3 XALience. 🔬 KLK2 × CD3, pasritamig + docetaxel (PASenger, TPS5139): already in randomized phase 3, n=800, rPFS primary. 🔬 DLL3 × CD3, tarlatamab (TIDAL, TPS5142): phase 2 in DLL3-positive neuroendocrine prostate, a setting with few options. 🔬 VEGF × PD-1, ivonescimab (NCT06567314): not a T-cell engager, testing the microenvironment in mCRPC. The targets are diversifying (STEAP1, KLK2, and DLL3 each handle prostate specificity differently), and the trials are moving earlier rather than sitting late salvage. Excited to follow this movement and the idea of an immune based therapy in this typically immune resistant tumor. #ProstateCA #mCRPC #GUonc #ASCO26 @OncoAlert

Rad2Nivo: Phase Ib study of Ra-223 with Nivo in mCRPC @urotoday #ASCO26 @ggebraelmd @neerajaiims @maughanonc 🌟n=35 🌟Gr 3-5 TEAEs: 38% 🌟VAF reduction: 15/25 (60%) 🌟Median PSA PFS: 3.15 mos (95% CI 2.79-4.70)

Breaking news #ASCO26 👉Ph3 PROTEUS trial👉Periop ADT + apalutamide in high-risk localized/locally advanced #prostatecancer undergoing radical prostatectomy👉↑ pathologic response (8.9% vs 1.0%) & 5-yr metastasis-free survival (78.2% vs 73.5%; HR 0.80) @urotoday @OncoAlert

Over a year ago we lost Felix, a giant in Cancer research to ….Cancer. Let us support @ASCO with a CDA in the honor of Dr Feng. support.conquer.org/p2p/site/nGSMo… #ASCO26 @OncoAlert @ConquerCancerFd

We need a lot more of these ribbons #ASCO26

Another banner year at ASCO for our fellowship, with six Young Investigator Awards awarded to our trainees. Congratulations to our outstanding fellows on this well-deserved recognition!

Unsung hero poster award for RCC. @OncHahn discusses muscle and fat changes in patient receiving either Len/Ev or Cabo with some interesting findings that complement standard toxicity data.

ABBV-969 delivered a median rPFS of 15.3 months (95% CI 9.8, NE) in heavily pretreated mCRPC, in patients who had already progressed on taxanes and/or PSMA radioligand therapy. First-in-human dose escalation, biomarker-unselected. Median follow-up 13.7 mo. 🎯 Confirmed ORR 44.8%, including 17% CR, median DOR 11.0 mo 🎯 PSA50 67.4% and PSA90 30.2% at doses ≥3 mg/kg, median DoR 10.8 mo 📊 Responses across liver, lung, and nodal lesions 🔍 Manageable safety: anemia (59%) and fatigue (53%) most common, Grade ≥3 TRAEs 46.9%. ILD/pneumonitis only at the top dose, which has been dropped Real activity in a post-taxane, post-RLT population that is running out of options. Dose optimization ongoing. Congrats to the authors. @TDorffOnc #ProstateCA #mCRPC #GUonc #ASCO26

Today, history was made #ASCO26 The results of #RASOLUTE302 were reported: median overall survival doubled for previously treated patients with metastatic #PancreaticCancer. As the room erupted in a well-deserved standing ovation, my thoughts went immediately to my high school friend, Cati. Cati died from metastatic pancreatic cancer less than a month after her diagnosis last year. She was only 37 years old & one of the kindest people I’ve ever known. She left behind her husband, young son, and countless family members and friends who loved her deeply. Cancer research never moves as quickly as any of us wish it would. Cati should still be here. But every breakthrough represents hope. Hope for more time, more memories, and more tomorrows. Tonight, I'm thinking of Cati and everyone we've lost while we continue pushing for better outcomes for all patients. 💜